Market closed
ADMA Biologics/$ADMA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Ticker
$ADMA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
624
Website
ADMA Biologics Metrics
BasicAdvanced
$4.6B
Market cap
132.46
P/E ratio
$0.15
EPS
0.61
Beta
-
Dividend rate
Price and volume
Market cap
$4.6B
Beta
0.61
52-week high
$20.31
52-week low
$3.56
Average daily volume
4.4M
Financial strength
Current ratio
6.874
Quick ratio
2.679
Long term debt to equity
74.498
Total debt to equity
75.104
Interest coverage (TTM)
4.30%
Management effectiveness
Return on assets (TTM)
15.07%
Return on equity (TTM)
20.77%
Valuation
Price to earnings (TTM)
132.463
Price to revenue (TTM)
13.589
Price to book
24.35
Price to tangible book (TTM)
24.88
Price to free cash flow (TTM)
67.873
Growth
Revenue change (TTM)
58.69%
Earnings per share change (TTM)
-177.75%
3-year revenue growth (CAGR)
78.45%
3-year earnings per share growth (CAGR)
-40.14%
What the Analysts think about ADMA Biologics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.
ADMA Biologics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ADMA Biologics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ADMA Biologics News
AllArticlesVideos
ADMA Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript
Seeking Alpha·4 hours ago
Did ADMA Biologics (ADMA) Commit Securities Fraud Resulting in 20% Stock Drop? Contact BFA Law about its Ongoing Investigation
Accesswire·11 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Accesswire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ADMA Biologics stock?
ADMA Biologics (ADMA) has a market cap of $4.6B as of November 08, 2024.
What is the P/E ratio for ADMA Biologics stock?
The price to earnings (P/E) ratio for ADMA Biologics (ADMA) stock is 132.46 as of November 08, 2024.
Does ADMA Biologics stock pay dividends?
No, ADMA Biologics (ADMA) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next ADMA Biologics dividend payment date?
ADMA Biologics (ADMA) stock does not pay dividends to its shareholders.
What is the beta indicator for ADMA Biologics?
ADMA Biologics (ADMA) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.